| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/30/2013 | CA2590811C Heterocycle derivatives as histone deacetylase (hdac) inhibitors |
| 07/30/2013 | CA2583973C Aminomethyl substituted bicyclic aromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 07/30/2013 | CA2580397C Aqueous pharmaceutical preparation comprising roflumilast and an alkoxylated fat |
| 07/30/2013 | CA2579720C A pharmaceutical composition for treating ataxia, multiple system atrophy or balance disorders |
| 07/30/2013 | CA2579121C Process for production of optically active amine derivatives |
| 07/30/2013 | CA2575472C Hiv inhibiting 5-substituted pyrimidines |
| 07/30/2013 | CA2569530C Thienopyrazole derivative having pde 7 inhibitory activity |
| 07/30/2013 | CA2564379C Aerosol formulation for inhalation of beta agonists |
| 07/30/2013 | CA2563400C Medicament for the treatment of fungal infections, particularly aspergillosis |
| 07/30/2013 | CA2561305C Tetrahydro-indazole cannabinoid modulators |
| 07/30/2013 | CA2547410C 1,2,3-triazole amide derivatives as inhibitors of cytokie production |
| 07/30/2013 | CA2539588C Fused pentacyclic polyethers |
| 07/30/2013 | CA2531856C Benzimidazole carboxamides as raf kinase inhibitors |
| 07/30/2013 | CA2523517C Bcl2l12 polypeptide activators and inhibitors |
| 07/30/2013 | CA2518944C Inhibitors of extracellular hsp90 |
| 07/30/2013 | CA2503630C Improved formulations containing substituted imidazole derivatives |
| 07/30/2013 | CA2483917C Formulations limiting spread of pulmonary infections |
| 07/30/2013 | CA2479764C Hemiasterlin derivatives and uses thereof |
| 07/30/2013 | CA2463158C Depot formulations of iloperidone and a star polymer |
| 07/30/2013 | CA2462886C Flashmelt oral dosage formulation |
| 07/30/2013 | CA2451874C Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells |
| 07/30/2013 | CA2425174C Human gene critical to fertility |
| 07/30/2013 | CA2422774C Remedies for amyotrophic lateral sclerosis |
| 07/30/2013 | CA2420854C Slow release pharmaceutical preparation and method of administering of same |
| 07/25/2013 | WO2013110085A1 Oral dosage forms for delivering metformin and sitagliptin |
| 07/25/2013 | WO2013110077A1 Topical therapeutic formulations |
| 07/25/2013 | WO2013110058A2 Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma |
| 07/25/2013 | WO2013110056A1 Biomaterials comprising hyaluronic acid binding peptides and bifunctional biopolymer molecules for hyaluronic acid retention and tissue engineering applications |
| 07/25/2013 | WO2013110010A1 Compositions and methods for incorporation of encapsulated materials in anhydrous materials |
| 07/25/2013 | WO2013110006A2 Compositions and methods of use of phorbol esters |
| 07/25/2013 | WO2013109998A1 Metalloenzyme inhibitor compounds |
| 07/25/2013 | WO2013109991A1 Substituted heterocyclic compounds for disease treatment |
| 07/25/2013 | WO2013109959A1 Hyaluronic acid particles and their use in biomedical applications |
| 07/25/2013 | WO2013109929A1 Methods of ganglioside production |
| 07/25/2013 | WO2013109906A2 Methods and formulations for treating sialic acid deficiencies |
| 07/25/2013 | WO2013109882A1 Substituted pyrimidine compounds and their use as syk inhibitors |
| 07/25/2013 | WO2013109876A1 Enhanced glycemic control using ad36e4orf1 and akt1 inhibitor |
| 07/25/2013 | WO2013109866A1 Flindersia alkaloids, derivatives and analogs: compositions and methods for producing the same |
| 07/25/2013 | WO2013109739A1 Tricyclic sulfonamide compounds and methods of making and using same |
| 07/25/2013 | WO2013109738A1 Novel phosphodiesterase inhibitors and uses thereof |
| 07/25/2013 | WO2013109735A1 Tricyclic sulfone compounds and methods of making and using same |
| 07/25/2013 | WO2013109732A2 Chitosan-derived compositions |
| 07/25/2013 | WO2013109632A2 Organic compounds |
| 07/25/2013 | WO2013109610A1 Pharmaceutical compositions and methods |
| 07/25/2013 | WO2013109543A1 Small molecule cmklr1 antagonists in demyelinating disease |
| 07/25/2013 | WO2013109521A1 Pyran-spirocyclic piperidine amides as modulators of ion channels |
| 07/25/2013 | WO2013109514A1 New forms and salts of a dihydropyrrolo[1,2-c]imidazolyl aldosterone synthase or aromatase inhibitor |
| 07/25/2013 | WO2013109388A2 1,5-naphthyridine derivatives and melk inhibitors containing the same |
| 07/25/2013 | WO2013109365A1 Vasoconstrictor for use in the treatment of abnormal uterine bleeding and apparatus for delivery thereof |
| 07/25/2013 | WO2013109323A2 Topical dtpa prodrug formulations and methods of using the same |
| 07/25/2013 | WO2013109292A1 A highly selective pyrophosphate sensor |
| 07/25/2013 | WO2013109241A1 Anti-obesity potential of calebin a |
| 07/25/2013 | WO2013109230A1 Pharmaceutical compositions comprising tadalafil |
| 07/25/2013 | WO2013109229A1 Tablet formulations comprising cefixime as active agent |
| 07/25/2013 | WO2013109228A1 Formulations comprising cefixime as active agent |
| 07/25/2013 | WO2013109227A1 Pharmaceutical compositions comprising ceftibuten |
| 07/25/2013 | WO2013109226A1 Pharmaceutical tablet formulations comprising cefuroxime |
| 07/25/2013 | WO2013109225A1 Pharmaceutical tablet formulations comprising ceftibuten |
| 07/25/2013 | WO2013109224A1 Pharmaceutical compositions comprising diclofenac |
| 07/25/2013 | WO2013109223A1 Particulate formulations of tadalafil in effervescent form |
| 07/25/2013 | WO2013109222A1 Formulations comprising diclofenac as the active agent |
| 07/25/2013 | WO2013109221A1 New effervescent formulations comprising sweetener composition |
| 07/25/2013 | WO2013109220A1 Dry powder formulations comprising tiotropium, formoterol and budesonide |
| 07/25/2013 | WO2013109219A1 Dry powder formulations comprising tiotropium and carmoterol |
| 07/25/2013 | WO2013109218A1 Dry powder formulations comprising carmoterol and ciclesonide |
| 07/25/2013 | WO2013109217A1 Pharmaceutical formulations comprising aztreonam |
| 07/25/2013 | WO2013109215A1 Preparation of dry powder formulations comprising formoterol |
| 07/25/2013 | WO2013109214A1 Process for the preparation of dry powder formulations |
| 07/25/2013 | WO2013109212A1 Dry powder formulations comprising ciclesonide |
| 07/25/2013 | WO2013109211A1 Dry powder formulations comprising r-formoterol as active agent |
| 07/25/2013 | WO2013109210A1 Dry powder formulations comprising budesonide |
| 07/25/2013 | WO2013109209A1 Dry powder formulations comprising fluticasone |
| 07/25/2013 | WO2013109208A1 Formulations comprising formoterol as active agent |
| 07/25/2013 | WO2013109207A1 Dry powder formulations comprising mometasone |
| 07/25/2013 | WO2013109206A1 Tablet formulations comprising cefuroxime |
| 07/25/2013 | WO2013109205A1 Pharmaceutical tablet formulations comprising cefetamet |
| 07/25/2013 | WO2013109204A1 Compositions comprising cefditoren pivoxil |
| 07/25/2013 | WO2013109203A1 Tablet formulations comprising cefditoren pivoxil |
| 07/25/2013 | WO2013109201A1 Pharmaceutical compositions comprising cefprozil and clavulanic acid |
| 07/25/2013 | WO2013109199A1 Effervescent pharmaceutical formulations comprising pregabalin and vitamin b12 |
| 07/25/2013 | WO2013109142A1 Combined pdk and mapk/erk pathway inhibition in neoplasia |
| 07/25/2013 | WO2013109057A1 Magnetic nanoparticle-samirna complex and method for preparing same |
| 07/25/2013 | WO2013109016A1 Novel use for melatonin |
| 07/25/2013 | WO2013108926A1 Prophylactic and therapeutic drug for amyotrophic lateral sclerosis and method of screening therefor |
| 07/25/2013 | WO2013108921A1 Industrial process for preparation of 1,2-dihydroquinoline derivative or a salt thereof, and intermediate for preparation thereof |
| 07/25/2013 | WO2013108857A1 Heterocyclic amide derivative and pharmaceutical product containing same |
| 07/25/2013 | WO2013108837A1 Pyrazole derivative with tlr inhibiting properties |
| 07/25/2013 | WO2013108822A1 Des(rhamnosyl) acteoside-containing olive extract |
| 07/25/2013 | WO2013108809A1 3,5-disubstituted alkynylbenzene compound and salt thereof |
| 07/25/2013 | WO2013108800A1 Substituted phenylazole derivative |
| 07/25/2013 | WO2013108794A1 Novel glycosyltransferase gene and use thereof |
| 07/25/2013 | WO2013108754A1 Pyrazine carboxamide compound |
| 07/25/2013 | WO2013108644A1 Rebamipide therapeutic agent for allergic conjunctivitis |
| 07/25/2013 | WO2013108428A1 Appetite suppressant |
| 07/25/2013 | WO2013108270A1 Curcumin coated magnetite nanoparticles for biomedical applications |
| 07/25/2013 | WO2013108263A1 Pharmaceutical formulation to reduce inflammation of bones and joint friction with improved cartilage quality |
| 07/25/2013 | WO2013108262A1 Synergistic combination for the treatment of diabetic neuropathy |
| 07/25/2013 | WO2013108235A1 Stabilized pth formulation |
| 07/25/2013 | WO2013108227A1 Heterocyclic amide derivatives as p2x7 receptor antagonists |
| 07/25/2013 | WO2013108180A1 Aqueous paracetamol composition for injection |